1. Generics Bulletin
  2. >>Business

UK-Based Morningside Snapped Up By US Private Equity

H.I.G Capital’s Aspire Pharma To Combine With Morningside

 
• By Dean Rudge

Aspire Pharma’s takeover of Morningside and its related subsidiaries will create “the UK’s premier Specialty Pharma company,” becoming one of “the largest and fastest growing UK pharma companies.”

Row of ticks
H.I.G. has swiftly closed the acquisition • Source: Shutterstock

UK-based Morningside Healthcare and its Morningside Pharmaceuticals business will have “greater scale, breadth and diversity across products, geographies, and sales channels,” after being acquired by H.I.G. Capital’s Aspire Pharma business and consolidated with the firm.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.